These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24139487)

  • 21. [Agents for the treatment of African sleeping sickness. Those developed in the last century].
    Schlitzer M
    Pharm Unserer Zeit; 2009; 38(6):552-8. PubMed ID: 19862727
    [No Abstract]   [Full Text] [Related]  

  • 22. Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein.
    Sanderson L; Dogruel M; Rodgers J; De Koning HP; Thomas SA
    J Pharmacol Exp Ther; 2009 Jun; 329(3):967-77. PubMed ID: 19261919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. African sleeping sickness.
    Hedley L; Fink D; Sparkes D; Chiodini PL
    Br J Hosp Med (Lond); 2016 Oct; 77(10):C157-C160. PubMed ID: 27723399
    [No Abstract]   [Full Text] [Related]  

  • 24. Existing chemotherapy and its limitations.
    Gutteridge WE
    Br Med Bull; 1985 Apr; 41(2):162-8. PubMed ID: 3161577
    [No Abstract]   [Full Text] [Related]  

  • 25. Anti-sleeping sickness drugs and cancer chemotherapy.
    Barrett SV; Barrett MP
    Parasitol Today; 2000 Jan; 16(1):7-9. PubMed ID: 10637579
    [No Abstract]   [Full Text] [Related]  

  • 26. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO).
    Iten M; Matovu E; Brun R; Kaminsky R
    Trop Med Parasitol; 1995 Sep; 46(3):190-4. PubMed ID: 8533023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story.
    Baker N; de Koning HP; Mäser P; Horn D
    Trends Parasitol; 2013 Mar; 29(3):110-8. PubMed ID: 23375541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Killer coma: the evolving story of sleeping sickness treatment.
    Lancet; 2010 Jan; 375(9709):93. PubMed ID: 20109869
    [No Abstract]   [Full Text] [Related]  

  • 29. Emerging compounds and therapeutic strategies to treat infections from
    Melfi F; Carradori S; Campestre C; Haloci E; Ammazzalorso A; Grande R; D'Agostino I
    Expert Opin Ther Pat; 2023 Mar; 33(3):247-263. PubMed ID: 36933190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
    Maina N; Maina KJ; Mäser P; Brun R
    Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis.
    Mpia B; Pépin J
    Trop Med Int Health; 2002 Sep; 7(9):775-9. PubMed ID: 12225509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
    Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates.
    Graf FE; Baker N; Munday JC; de Koning HP; Horn D; Mäser P
    Int J Parasitol Drugs Drug Resist; 2015 Aug; 5(2):65-8. PubMed ID: 26042196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.
    Graf FE; Ludin P; Wenzler T; Kaiser M; Brun R; Pyana PP; Büscher P; de Koning HP; Horn D; Mäser P
    PLoS Negl Trop Dis; 2013; 7(10):e2475. PubMed ID: 24130910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
    Amilon C; Boberg M; Tarning J; Äbelö A; Ashton M; Jansson-Löfmark R
    AAPS J; 2022 Mar; 24(3):48. PubMed ID: 35338410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro drug sensitivity of Trypanosoma gambiense isolates.
    Brun R; Baeriswyl S; Kunz C
    Acta Trop; 1989 Oct; 46(5-6):369-76. PubMed ID: 2575872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current therapy of trypanosomiasis].
    Doua F; Boa Yapo F
    Bull Soc Pathol Exot; 1994; 87(5):337-40. PubMed ID: 7496197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of human African trypanosomiasis--present situation and needs for research and development.
    Legros D; Ollivier G; Gastellu-Etchegorry M; Paquet C; Burri C; Jannin J; Büscher P
    Lancet Infect Dis; 2002 Jul; 2(7):437-40. PubMed ID: 12127356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis.
    Doua F; Miezan TW; Sanon Singaro JR; Boa Yapo F; Baltz T
    Am J Trop Med Hyg; 1996 Dec; 55(6):586-8. PubMed ID: 9025682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The return of sleeping sickness in an epidemic form: international action for drugs].
    Kager PA
    Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2527-30. PubMed ID: 12532663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.